Abcam, ab275933, Anti-C5 / C5b antibody [EPR23940-3] - BSA and Azide free

Size: 100µg / 1mg
Rabbit Recombinant Monoclonal C5 antibody. Carrier free. Suitable for IHC-P, WB and reacts with Mouse, Rat, Human samples. Cited in 1 publication.
Key facts
Host species:Rabbit,
Clonality:Monoclonal,
Clone number:EPR23940-3,
Isotype:IgG1,
Carrier free:Yes,
Reacts with:Mouse, Rat, Human,
Applications:WB, IHC-PSee reactivity dataSee the reactivity data table below for information on validated species and application combinations.,
Immunogen:The exact immunogen used to generate this antibody is proprietary information.

Product details:
ab275933 is the carrier-free version of
ab275931
Patented technology
Our RabMAb
technology is a patented hybridoma-based technology for making rabbit monoclonal antibodies. For details on our patents, please refer to
RabMAb® patents
What are the advantages of a recombinant monoclonal antibody?
This product is a recombinant monoclonal antibody, which offers several advantages including:
- High batch-to-batch consistency and reproducibility
- Improved sensitivity and specificity
- Long-term security of supply
- Animal-free batch production
For more information, read more on
recombinant antibodies
Conjugation ready
Our carrier-free antibodies are typically supplied in a PBS-only formulation, purified and free of BSA, sodium azide and glycerol. This conjugation-ready format is designed for use with fluorochromes, metal isotopes, oligonucleotides, and enzymes, which makes them ideal for antibody labelling, functional and cell-based assays, flow-based assays (e.g. mass cytometry) and Multiplex Imaging applications.
Use our
conjugation kits
for antibody conjugates that are ready-to-use in as little as 20 minutes with 1 minute hands-on-time and 100% antibody recovery: available for fluorescent dyes, HRP, biotin and gold.
Compatibility
This product is compatible with the Maxpar
Antibody Labeling Kit from Fluidigm, without the need for antibody preparation. Maxpar
is a trademark of Fluidigm Canada Inc.

Properties and Storage Information:
Form-Liquid, Purification technique-Affinity purification Protein A, Storage buffer-Constituents: PBS, Shipped at conditions-Blue Ice, Appropriate short-term storage conditions-+4°C, Appropriate long-term storage conditions-+4°C

Supplementary Information:
This supplementary information is collated from multiple sources and compiled automatically.
The C5 molecule also known as complement component 5 is an essential part of the complement system which is part of the immune response. This protein has an approximate molecular weight of 190 kDa and is mainly expressed in the liver circulating in plasma. Upon activation C5 is cleaved into C5a and C5b fragments. The C5b fragment plays an important role in forming the membrane attack complex (MAC) by binding to other complement proteins. The cleavage and activation of C5 are necessary for initiating the assembly of the MAC.
Biological function summary
C5 facilitates the destruction of pathogens by forming the membrane attack complex with other complement proteins such as C6 C7 C8 and C9. C5b acts as a binding site for these proteins leading to a cascade that eventually creates a pore in the pathogen's membrane causing cell lysis. This role in the complement system places C5 as an essential player in innate immunity helping the body eliminate bacteria and foreign cells through direct lysis.
Pathways
C5 functions within the complement pathway specifically in the terminal (lytic) pathway. This pathway has two branches: the classical pathway initiated by antibody-antigen complexes and the alternative pathway activated directly on pathogen surfaces. Both pathways lead to the cleavage of C5 by the C5 convertase resulting in engagement of C5b with C6 C7 C8 and C9 to form the MAC. C5 works closely with other complement proteins including C3 and C4 linking the initial phase of activation to the execution of cell lysis.
C5 has significant connections to conditions such as paroxysmal nocturnal hemoglobinuria (PNH) and atypical hemolytic uremic syndrome (aHUS). These diseases result from dysregulation of the complement system and can lead to excessive activation of C5 and the formation of MAC causing damage to host cells. Eculizumab a monoclonal antibody targeting C5 has been used in treatment by inhibiting C5 activation and preventing the formation of the MAC. This intervention reduces hemolysis and other symptoms associated with these disorders.